Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
Balance Sheet
Inspect the capital base behind the business.
Assets
$116.48M
FY 2025 · Annual
-27.3% YoYLiabilities
$5.10M
FY 2025 · Annual
+14.5% YoYEquity
$111.38M
FY 2025 · Annual
-28.5% YoYBalance Sheet
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $36.6M |
| Short-term Investments | $67.9M |
| Other Current | $3.2M |
| Total Current Assets | $107.7M |
| PP&E (Net) | $39.0K |
| Total Non-current Assets | $39.0K |
| Total Assets | $107.8M |
Analysis
Selected assets total $107.8M for Latest. The largest visible component is Short-term Investments at $67.9M, about 63.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 8-K | Current report | Oct 22, 2026 | |
| SC 13G | SC 13G filing | Oct 7, 2026 |
How much cash does SGMT have?
Sagimet Biosciences Inc. (SGMT) reported $35.02M in cash and equivalents in fiscal 2025.
How much debt does SGMT carry?
Sagimet Biosciences Inc. (SGMT) reported $78,000.00 of total debt, with net debt of -$34.94M.
Continue the stock analysis
Jump to another research area for this company.